In the present study, we sought to determine the prognostic performance of the TAPSE/sPAP ratio along with the suggested 2015 ESC/ERS 3-strata model (categorizing risk as low, intermediate, or high) at the time of diagnosis13 in predicting outcomes and improving risk stratification and reclassification in patients with PAH (group 1). The gene discussed is PDZK1IP1; the disease is pulmonary arterial hypertension.